Psilocybins & Ayahuasca
Psilocybin and its active metabolite, psilocin, exert their effects primarily through serotonin 5-HT2A receptor agonism, leading to profound alterations in perception, cognition, and mood. Psilocybin itself is a prodrug that is rapidly dephosphorylated into psilocin upon ingestion, which then crosses the blood-brain barrier and interacts with serotonergic neurotransmission. Psilocin structurally resembles serotonin (5-hydroxytryptamine, 5-HT) and binds to multiple serotonin receptor subtypes, with the highest affinity for 5-HT2A receptors in the prefrontal cortex. Activation of these receptors initiates a cascade of intracellular signaling changes, including increased excitatory neurotransmission and synaptic plasticity, which are believed to underlie its psychedelic effects.
One of the primary consequences of 5-HT2A receptor activation is the disruption of normal thalamocortical processing. The thalamus, which typically filters sensory information before it reaches higher-order cortical regions, becomes less restrictive under psilocin’s influence, allowing an increased flow of sensory input to reach the cortex. This results in intensified sensory perception, synesthetic experiences, and altered time perception. Additionally, psilocybin modulates connectivity within large-scale brain networks, particularly increasing communication between normally segregated brain regions while reducing activity in the default mode network (DMN), a network associated with self-referential thoughts and ego-related processing. This temporary disintegration of the DMN is thought to contribute to ego dissolution, mystical experiences, and the therapeutic potential of psilocybin in conditions such as depression and anxiety.
Psilocybin also influences the release of other neurotransmitters, including dopamine and glutamate, which contribute to its cognitive and emotional effects. By increasing glutamatergic activity in the prefrontal cortex, psilocybin enhances neural plasticity, promoting changes in thought patterns and emotional processing. This mechanism is believed to underlie its long-term antidepressant and anxiolytic effects observed in clinical studies.
Common psilocybin-containing compounds include psilocybin itself and its metabolite psilocin, as well as related tryptamine alkaloids such as baeocystin and norbaeocystin, found in various species of psychedelic mushrooms. Psilocybin-containing mushrooms include Psilocybe cubensis, Psilocybe semilanceata, and Psilocybe azurescens, among others. While psilocin is the primary psychoactive compound responsible for the psychedelic experience, the presence of minor alkaloids may contribute to variations in effects between different mushroom species.
Ayahuasca is a psychoactive brew traditionally used in Amazonian shamanic practices, composed of a combination of plants, most commonly Banisteriopsis caapi and Psychotria viridis. Its effects stem from the interaction between β-carboline alkaloids found in B. caapi and the psychedelic tryptamine N,N-dimethyltryptamine (DMT) found in P. viridis. The pharmacological action of ayahuasca involves serotonin receptor activation, inhibition of monoamine oxidase (MAO), and modulation of multiple neurotransmitter systems, leading to profound alterations in perception, cognition, and emotional processing.
The primary psychoactive compound in ayahuasca, DMT, is a potent serotonin 5-HT2A receptor agonist, similar to psilocin and LSD. However, unlike those compounds, DMT is typically metabolized rapidly by monoamine oxidase enzymes in the gastrointestinal tract, rendering it inactive when ingested orally. The β-carboline alkaloids in B. caapi, including harmine, harmaline, and tetrahydroharmine, act as reversible inhibitors of monoamine oxidase A (MAO-A), preventing the breakdown of DMT and allowing it to reach the bloodstream and cross the blood-brain barrier. Once in the brain, DMT binds to 5-HT2A receptors, triggering a cascade of intracellular signaling processes that enhance excitatory neurotransmission, disrupt thalamocortical filtering, and alter large-scale brain network connectivity. This results in vivid visual hallucinations, synesthetic experiences, changes in time perception, and alterations in self-awareness, often described as mystical or transcendental.
Beyond its serotonergic effects, ayahuasca also influences dopamine and glutamate systems. Increased glutamatergic activity in the prefrontal cortex, likely mediated by 5-HT2A receptor activation, enhances synaptic plasticity and may contribute to the brew’s therapeutic potential in conditions such as depression, anxiety, and post-traumatic stress disorder. The β-carboline alkaloids, particularly tetrahydroharmine, also exhibit weak serotonin reuptake inhibition, which may further contribute to mood-enhancing effects. Additionally, harmine and harmaline have been shown to promote neurogenesis and exhibit neuroprotective properties, which could underlie some of the long-term psychological benefits associated with ayahuasca use.
The combination of psilocybin and ayahuasca would likely produce an intense and prolonged psychedelic experience due to their overlapping mechanisms of action, primarily through serotonin 5-HT2A receptor agonism.
If taken together, psilocybin would act in parallel with DMT, likely leading to a synergistic enhancement of serotonergic activity, resulting in more vivid hallucinations, intensified emotional experiences, and potentially greater neuroplasticity effects.
Another consideration is the β-carboline alkaloids in ayahuasca, particularly harmine, harmaline, and tetrahydroharmine, which not only inhibit MAO-A but also have mild serotonin reuptake inhibition and dopamine-modulating properties. This could lead to a more complex and prolonged psychedelic state by affecting serotonin metabolism and synaptic availability. MAO-A inhibition might also slow down the metabolism of psilocin, effectively extending and intensifying its effects beyond the typical psilocybin experience.
Physiologically, combining these substances could lead to stronger autonomic effects, including increased heart rate, blood pressure fluctuations, nausea, and vomiting. The purgative nature of ayahuasca could be exacerbated, making the experience more physically intense.
Cognitively and emotionally, this combination might result in a deeper dissociation from the ego and a more profound state of altered consciousness. However, the increased intensity might also make the experience more difficult to navigate, increasing the likelihood of anxiety, paranoia, or overwhelming psychological distress.
The risk of serotonin syndrome when combining psilocybin and ayahuasca is possible but likely remains low under typical use, assuming reasonable doses. Both substances act primarily as serotonin 5-HT2A receptor agonists, but serotonin syndrome is usually caused by excessive serotonergic activity at 5-HT1A and 5-HT2A receptors, along with increased synaptic serotonin levels due to monoamine oxidase inhibitors (MAOIs) or serotonin reuptake inhibitors (SSRIs).
Ayahuasca contains β-carboline alkaloids such as harmine, harmaline, and tetrahydroharmine, which act as reversible MAO-A inhibitors, preventing the breakdown of monoamines like serotonin, dopamine, and norepinephrine. This raises concerns about serotonin accumulation when combined with another serotonergic substance like psilocybin, which directly activates serotonin receptors. However, psilocybin itself does not significantly increase serotonin levels in the synapse the way SSRIs or MDMA do. Instead, it primarily acts as a receptor agonist without substantially interfering with serotonin metabolism.
The main concern for serotonin syndrome would arise if the inhibition of MAO-A by ayahuasca significantly slowed the metabolism of psilocin, potentially leading to prolonged and excessive serotonergic stimulation. This could be more problematic with high doses, individual sensitivity, or pre-existing serotonergic dysregulation. Symptoms of serotonin syndrome include agitation, confusion, hyperthermia, increased heart rate, muscle rigidity, tremors, and autonomic instability.
Given the lack of clinical studies on this combination, caution is warranted, especially for individuals with a history of psychiatric or cardiovascular conditions. While the risk appears lower than with combinations involving SSRIs or MAOIs with synthetic psychedelics, careful dose management and monitoring would be essential to avoid potential adverse effects.
This combination requires a lot of experience with substances separately, compliance with minimum dosages, meaningful approach and great caution.
Last edited by a moderator: